HLS Therapeutics Inc. (HLS.TO)
- Previous Close
4.8100 - Open
4.8000 - Bid 4.7500 x --
- Ask 4.8200 x --
- Day's Range
4.7100 - 4.8000 - 52 Week Range
3.0000 - 4.9800 - Volume
1,770 - Avg. Volume
9,953 - Market Cap (intraday)
148.998M - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8000 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 27, 2023
- 1y Target Est
6.38
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
www.hlstherapeutics.com92
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HLS.TO
View MorePerformance Overview: HLS.TO
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLS.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLS.TO
View MoreValuation Measures
Market Cap
149.00M
Enterprise Value
213.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.89
Price/Book (mrq)
1.60
Enterprise Value/Revenue
2.69
Enterprise Value/EBITDA
8.63
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.71%
Return on Assets (ttm)
-2.60%
Return on Equity (ttm)
-23.25%
Revenue (ttm)
56.62M
Net Income Avi to Common (ttm)
-19.66M
Diluted EPS (ttm)
-0.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
17.46M
Total Debt/Equity (mrq)
93.14%
Levered Free Cash Flow (ttm)
26.39M